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Gestational diabetes mellitus (GDM) is associated with an increased long-term risk of developing diabetes. We investigated
the risk factors for early postpartum glucose intolerance in patients with GDM.
A total of 148 patients with GDM were included in this study. Among them, 30 and 118 were diagnosed with GDM before
(B20w group) and after (A20w group) 20 weeks of gestation, respectively. Oral glucose tolerance test (OGTT) was per-
formed in all patients 58 days after delivery. In each group, the association between the postpartum OGTT results and the fol-
lowing parameters were analyzed: age, BMI, family history of diabetes, plasma glucose levels in diagnostic prenatal OGTT,
number of abnormal OGTT values, glycated hemoglobin and glycated albumin (GA) levels at diagnosis of GDM, serum C-
peptide levels, frequency of insulin therapy, and pregnancy outcomes.
Postpartum OGTT revealed glucose intolerance in 9 and 35 patients in the B20w and A20w groups, respectively. In the
B20w group, placental weight was an independent predictor for glucose intolerance. In the A20w group, GA level and family
history were independent predictors for glucose intolerance.
Elevated GA levels may be associated with a higher risk of postpartum glucose intolerance in patients with GDM diagnosed
after 20 weeks of gestation.
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Introduction
Gestational diabetes mellitus (GDM) increases the risk of
adverse pregnancy outcomes such as perinatal mortality,
macrosomia, shoulder dystocia, preeclampsia, cesarean
section, and neonatal complications. In addition, GDM is
an associated with increased long-term risk of diabetes in
mothers. A meta-analysis showed that women with a his-
tory of GDM had a seven-fold higher risk of developing
type 2 diabetes than those who had normal glucose toler-
ance during pregnancy.
１
A systematic literature review
reported a markedly increased risk for developing type 2
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diabetes within the first five years after a pregnancy with
GDM.
２
Therefore, the diagnosis of GDM offers the op-
portunity for identifying women at a high risk of devel-
oping glucose intolerance in the future. Some guidelines
recommend a follow-up of women after a pregnancy
with GDM.
３，４
In the Guidelines for obstetrical practice in
Japan, 2020 edition, women with GDM are recom-
mended to undergo a 75-g oral glucose tolerance test
(OGTT) 6-12 weeks after delivery.
３
The American Dia-
betes Association recommends that women with GDM
should undergo OGTT at 4-12 weeks postpartum with re-
peat tests every 1-3 years if the postpartum OGTT is nor-
mal.
４
However, the number of women with a history of
GDM who were followed up in the postpartum period
was reported to be inadequately low.
５-１０
Hence, a large
number of women with a history of GDM developing
type 2 diabetes may be neglected without testing.
In Japan, the number of women with GDM increased
by at least 2.7-fold after adopting the International Asso-
ciation of Diabetes and Pregnancy Study Groups
( IADPSG ) Criteria.
１１
It has been reported that Asian
women with GDM were associated with a higher risk of
impaired glucose tolerance during the early postpartum
period.
１２，１３
Therefore, identifying women who have im-
paired glucose tolerance during the early postpartum pe-
riod is important to facilitate follow-up management of
women with GDM. The aim of this study was to assess
potential predictors of early postpartum glucose intoler-
ance in Japanese women with GDM diagnosed according
to the IADPSG criteria.
Subjects and Methods
1．Subjects
We investigated a total of 154 women who were diag-
nosed with GDM using the IADPSG criteria and under-
went an OGTT between 1-5 months after delivery at the
Tokyo Women’s Medical University Medical Center
East, from April 2012 to February 2016. Among them,
148 women who had a singleton pregnancy were in-
cluded in this study. Their median age was 35 (31, 38)
years, and their median pre-gestational body mass index
(BMI) was 21.7 (19.9, 24.7) kg/m
2
. In our hospital, the
two-step screening test for GDM was performed for each
woman, and it was recommended for all of them to un-
dergo a diagnostic OGTT when the random plasma glu-
cose level was more than 100 mg/dL in early pregnancy
or the plasma glucose level after a 50-g glucose chal-
lenge test exceeded 140 mg/dL in mid-pregnancy. Our
hospital is a local core hospital where more than 30% of
the women with GDM were referred from other hospi-
tals. The subjects were divided into two groups according
to the time of diagnosis of GDM: those diagnosed before
(B20w group) and those diagnosed after (A20w group)
20 weeks of gestation.
2．Study methods
Glycated hemoglobin (HbA1c) and glycated albumin
(GA) levels were measured at the time of GDM diagno-
sis or at the first visit to our hospital if the subject was re-
ferred to our hospital after the diagnosis, and the levels of
C-peptide, triglycerides, high density lipoprotein (HDL)-
cholesterol, and low density lipoprotein ( LDL ) -
cholesterol were measured in fasting blood samples at the
second visit, usually at 2 weeks after the first visit. After
the women received dietary counselling (30 kcal/kg ideal
body weight + 200 kcal) from a registered dietitian, if
they had elevated fasting plasma glucose levels (> 100
mg/dL) or their 2h-postprandial glucose levels exceeded
120 mg/dL despite nutritional therapy and exercise, treat-
ment with insulin commenced. An OGTT was performed
on all subjects 58.0 ± 13.3 days after delivery. The sub-
jects in the B20w and A20w groups were further divided
into the following two subgroups: normal group, women
with normal glucose tolerance; GI group, women with
glucose intolerance including diabetes, impaired glucose
tolerance or impaired fasting glucose according to the
World Health Organization criteria.
１４
We evaluated the association between the results of
postpartum OGTT and the following parameters: mater-
nal age, height, pre-gestational body weight, pre-
gestational BMI, family history of diabetes, number of
parity, smoking status, number of abnormal values at di-
agnostic prenatal OGTT, gestational age at diagnosis of
GDM, levels of plasma glucose in diagnostic prenatal
OGTT, fasting serum C-peptide, triglycerides, HDL-
cholesterol, LDL-cholesterol, HbA 1 c and GA, blood
pressure and the pregnancy outcomes including weight
gain during pregnancy, frequency of insulin therapy dur-
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ing pregnancy, the gestational age at delivery, cesarean
section, hypertensive disorders of pregnancy ( HDP ) ,
birth weight and sex of neonate, placental weight, and
neonatal complications such as respiratory problems, hy-
poglycemia, hyperbilirubinemia, congenital malforma-
tion, and neonatal intensive care unit (NICU) admission.
Among neonatal complications, respiratory problems in-
cluded respiratory distress syndrome, transient tachypnea
of the newborn, apnea, and other respiratory disorders re-
quiring clinical management. Neonatal hypoglycemia
was defined as a blood glucose level in the neonate be-
low 50 mg/dL. Neonates with hyperbilirubinemia under-
went phototherapy. Congenital malformations were de-
fined as structural or functional anomalies that impede
life or those that cause dysfunction requiring surgical in-
tervention. BMI was calculated using the following for-




Plasma glucose was determined by the hexokinase UV
method (Labospect 7700, Hitachi, Tokyo, Japan) using
Serotec GLU-HL (Serotec Co., Ltd. , Sapporo, Japan).
HbA1c level was analyzed by high-performance liquid
chromatography assay (automated glycohemoglobin ana-
lyzer HLC
Ⓡ
-723G9; Tosoh Corp., Tokyo, Japan). GA
was measured by an enzymatic method using a Lucica
GA-L kit (Asahi Kasei Pharma,Tokyo, Japan). Serum C-
peptide was determined by chemiluminescent enzyme
immunoassay ( Lumipulse Presto II ; Fujirebio, Inc.,
Tokyo, Japan) using the Lumipulse Presto C-peptide re-
agent. Triglycerides, HDL-cholesterol, and LDL-
cholesterol levels were measured using colorimetric
analysis (LABSPECT 008, Hitachi Ltd.).
This study was conducted in accordance with the ethi-
cal standards of the responsible committees on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1964 and later versions. In-
formed consent or a substitute for it was obtained from
all subjects. This study was approved by the Ethical
Committee of Tokyo Women’s Medical University (Ap-
proval No. 4110R2, approval date: June 2, 2017).
3．Statistical analysis
All data were reported as mean ± standard deviation,
median and inter-quartile range or a percentage of fre-
quencies. We used the Student’s t-test or Mann-Whitney
U test and chi-square test to examine differences in con-
tinuous and categorical variables between the two
groups, respectively. Subsequently, variables which were
significantly related to postpartum glucose intolerance
were included in the logistic regression analyses using
enter method. All analyses were conducted using SPSS
Statistics version 21 for Windows (IBM Corp., Armonk,
NY, USA). A p-value of < 0.05 was considered to indi-
cate statistical significance.
Results
1．Maternal characteristics in the B20w and A20w
groups
Thirty women were diagnosed with GDM before 20
weeks of gestation (B20w group) and 118 women were
diagnosed with GDM after 20 weeks of gestation (A20w
group). The B20w group had higher pre-pregnancy BMI,
fasting plasma glucose levels at diagnostic prenatal
OGTT, and lower triglyceride levels than the A 20 w
group (Table 1). Maternal age, frequencies of nullipa-
rous women and family history of diabetes, levels of
HbA1c and GA at diagnosis of GDM, and fasting serum
C-peptide levels were similar between the two groups.
Regarding pregnancy outcomes, the B20 w group had
higher frequency of insulin therapy during pregnancy and
lower gestational weight gain than the A 20 w group.
There were no differences between the two groups in
terms of gestational age at delivery, frequency of cesar-
ean section, birth weight of neonate, and frequency of
neonatal complications.
2．Association of postpartum glucose tolerance
status and clinical factors in the B20w group
In the B20w group, postpartum OGTT revealed glu-
cose intolerance in 9 (30%) women (GI subgroup) [im-
paired glucose tolerance (IGT), 7; impaired fasting glu-
cose (IFG)/IGT, 2] (Table 2).
Women in the GI subgroup had higher fasting glucose
levels on OGTT at diagnosis of GDM than those in the
normal subgroup. The number of abnormal values of di-
agnostic prenatal OGTT and, 1h- and 2h-glucose levels
tended to be higher in the GI subgroup without any sig-
nificant difference. There were no significant differences
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Table　1　Clinical characteristics of women in the B20w and A20w groups.
B20w group A20w group
p
 (n = 30)  (n = 118) 
Maternal characteristics
Age (years) 36 (34, 39) 35 (31, 38) 0.290
Height (cm) 157.9 ± 5.2 158.8 ± 5.1 0.414
Pre-pregnancy body weight (kg) 62 (52, 83) 54 (49, 61) 0.008
Pre-pregnancy BMI (kg/m2) 23.9 (20.7, 32.0) 21.4 (19.7, 23.7) 0.004
Nulliparous, n (%) 13 (43) 72 (61) 0.099
Family history of DM, n (%) 12 (40) 60 (51) 0.313
Smoking, n (%) 7 (23) 26 (22) 1.000
GDM diagnosis
Gestational age at diagnosis (weeks) 15.0 (13.1, 16.6) 27.8 (22.9, 30.0) <0.001
OGTT plasma glucose (mg/dL)
fasting 90 (81, 93) 83 (78, 92) 0.011
1h 186 (149, 213) 180 (159, 192) 0.058
2h 155 (144, 166) 157 (141, 169) 0.513
Number of abnormal values
1 point, n (%) 13 (43) 75 (64) 0.113
2 points, n (%) 12 (40) 33 (28) 
3 points, n (%) 5 (17) 10 (8) 
HbA1c (%) 5.4 ± 0.4 5.3 ± 0.4 0.065
GA (%) 13.2 ± 1.4 13.1 ± 1.1 0.856
Fasting serum C-peptide (mg/dL) 1.41 (0.97, 1.72) 1.45 (1.13, 1.93) 0.389
Systolic blood pressure (mmHg) 112 ± 14 109 ± 11 0.378
Diastolic blood pressure (mmHg) 63 (57, 69) 61 (56, 65) 0.351
Serum lipid profiles
Triglycerides (mg/dL) 170 (115, 228) 211 (169, 282) 0.005
HDL-cholesterol (mg/dL) 79 ± 17 83 ± 17 0.319
LDL-cholesterol (mg/dL) 135 (116, 158) 141 (120, 166) 0.457
Pregnancy outcome
Insulin therapy during pregnancy, n (%) 16 (53) 33 (28) 0.016
HDP, n (%) 2 (7) 8 (7) 1.000
Gestational weight gain (kg) 5.3 ± 6.0 8.4 ± 4.1 0.012
Gestational age at delivery (weeks) 38.7 (38.0, 39.3) 39.0 (38.3, 39.4) 0.096
Cesarean section, n (%) 9 (30) 38 (32) 1.000
Male sex, n (%) 17 (57) 63 (53) 0.839
Birth weight (g) 3,026 ± 493 2,996 ± 417 0.740
Placental weight (g) 540 (490, 650) 535 (490, 610) 0.886
Neonatal complication
Congenital malformation, n (%) 0 0
Hypoglycemia, n (%) 2 (7) 11 (9) 1.000
Hyperbilirubinemia, n (%) 0 2 (2) 
Respiratory problem, n (%) 4 (13) 14 (12) 0.762
NICU admission, n (%) 7 (23) 26 (22) 1.000
Data are shown as mean ± standard deviation, median and inter-quartile range in the parenthesis, or num-
ber and percentage in the parenthesis.
B20w group, the subjects diagnosed before 20 weeks of gestation; A 20w group, the subjects diagnosed af-
ter 20 weeks of gestation; BMI, body mass index; DM, diabetes mellitus; GDM, gestational diabetes melli-
tus; OGTT, 75-g oral glucose tolerance test; HbA1c, glycated hemoglobin; GA, glycated albumin; HDL, 
high density lipoprotein; LDL, low density lipoprotein; HDP, hypertensive disorders of pregnancy; NICU, 
neonatal intensive care unit.
in maternal age, pre-pregnancy BMI, and levels of
HbA1c, GA and fasting serum C-peptide between the
two subgroups. Women in the GI subgroup had higher
placental weight than those in the normal subgroup.
Multiple logistic regression analysis showed that pla-
cental weight was an independent predictor for glucose
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pNormal GI Normal GI
 (n = 21)  (n = 9)  (n = 83)  (n = 35) 
Maternal characteristics
Age (years) 37 (33, 39) 35 (34, 36) 0.326 34.4 ± 4.7 34.2 ± 3.3 0.759
Height (cm) 157.3 ± 5.3 159.4 ± 5.1 0.309 159.1 ± 5.1 158.2 ± 5.0 0.393
Pre-pregnancy body weight (kg) 60 (50, 75) 82 (53, 84) 0.226 54 (50, 60) 55 (48, 61) 0.675
Pre-pregnancy BMI (kg/m2) 22.7 (21.1, 30.7) 31.6 (20.7, 32.5) 0.372 21.4 (19.7, 23.2) 21.9 (19.8, 24.1) 0.960
Nulliparous, n (%) 10 (48) 3 (33) 0.691 51 (61) 21 (60) 1.000
Family history of DM, n (%) 9 (43) 3 (33) 0.704 37 (45) 23 (66) 0.045
Smoking, n (%) 3 (14) 4 (44) 0.153 21 (25) 5 (14) 0.230
GDM diagnosis
Gestational age at diagnosis (weeks) 15.0 ± 2.6 14.3 ± 2.0 0.459 25.7 (23.7, 30.0) 28.7 (25.4, 29.9) 0.110
OGTT plasma glucose (mg/dL)
fasting 88.2 ± 8.4 90.9 ± 9.4 0.013 84.4 ± 8.6 83.7 ± 10.5 0.712
1h 183 (146, 210) 200 (184, 217) 0.150 174.3 ± 25.7 174.8 ± 31.9 0.930
2h 145.0 ± 32.5 169.8 ± 25.9 0.053 157 (135, 165) 162 (153, 179) 0.051
Number of abnormal values
1 point, n (%) 12 (57) 1 (11) 0.050 55 (66) 20 (57) 0.596
2 points, n (%) 7 (33) 5 (56) 21 (25) 12 (34) 
3 points, n (%) 2 (10) 3 (33) 7 (8) 3 (9) 
HbA1c (%) 5.4 ± 0.3 5.6 ± 0.4 0.182 5.3 (5.0, 5.5) 5.2 (5.0, 5.6) 0.831
GA (%) 13.1 ± 1.3 13.3 ± 1.7 0.644 12.9 ± 1.0 13.6 ± 1.2 0.001
Fasting serum C-peptide (mg/dL) 1.40 (0.97, 1.66) 1.46 (1.11, 1.85) 0.476 1.40 (1.13, 1.83) 1.55 (1.11, 2.02) 0.631
Systolic blood pressure (mmHg) 113 ± 14 108 ± 14 0.371 109 ± 11 110 ± 10 0.458
Diastolic blood pressure (mmHg) 63 ± 9 64 ± 8 0.660 61 (57, 65) 60 (55, 67) 0.908
Serum lipid profiles
Triglycerides (mg/dL) 180 ± 74 179 ± 106 0.977 211 (174, 282) 211 (167, 275) 0.701
HDL-cholesterol (mg/dL) 81 ± 15 77 ± 20 0.584 82 (71, 94) 82 (71, 94) 0.824
LDL-cholesterol (mg/dL) 135 (128, 151) 116 (96, 158) 0.226 149 ± 37 133 ± 40 0.051
Pregnancy outcome
Insulin therapy during pregnancy, n (%) 11 (52) 5 (56) 1.000 18 (22) 15 (43) 0.025
HDP, n (%) 1 (5) 1 (11) 0.517 5 (6) 3 (9) 0.693
Gestational weight gain (kg) 6.1 ± 5.2 3.6 ± 7.5 0.303 8.4 ± 4.5 8.3 ± 3.1 0.799
Gestational age at delivery (weeks) 38.4 (38.0, 39.3) 38.7 (38.1, 39.0) 0.859 39.1 (38.3, 39.7) 38.9 (38.1, 39.4) 0.132
Cesarean section, n (%) 6 (29) 3 (33) 1.000 26 (31) 12 (34) 0.830
Male sex, n (%) 11 (52) 6 (67) 0.691 47 (57) 16 (46) 0.316
Birth weight (g) 2,974 3,130 0.094 3,037 ± 387 2,900 ± 472 0.102
 (2,774, 3,136)  (3,070, 3,292) 
Placental weight (g) 533 ± 86 632 ± 132 0.020 559 ± 98 542 ± 103 0.398
Neonatal complication
Congenital malformation, n (%) 0 0 0 0
Hypoglycemia, n (%) 0 2 (22) 8 (10) 3 (9) 1.000
Hyperbilirubinemia, n (%) 0 0 2 (2) 0
Respiratory problem, n (%) 3 (14) 1 (11) 1.000 11 (13) 3 (9) 0.551
NICU admission, n (%) 4 (19) 3 (33) 0.640 18 (22) 8 (23) 1.000
OGTT after delivery (days) 59.1 ± 12.3 58.3 ± 11.4 0.867 54 (49, 65) 56 (46, 64) 0.604
Data are shown as mean ± standard deviation, median and inter-quartile range in the parenthesis, or number and percentage in the parenthesis.
B20w group, the subjects diagnosed before 20 weeks of gestation; A 20w group, the subjects diagnosed after 20 weeks of gestation; GI, glucose intol-
erance; BMI, body mass index; DM, diabetes mellitus; GDM, gestational diabetes mellitus; OGTT, 75-g oral glucose tolerance test; HbA1c, glycated 
hemoglobin; GA, glycated albumin; HDL, high density lipoprotein; LDL, low density lipoprotein; HDP, hypertensive disorders of pregnancy; NICU, 
neonatal intensive care unit.
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Table　3　Logistic regression analysis of predictors for postpar-
tum glucose intolerance in the B20w and A20w groups.
Odds ratio
p
 (95% confidence interval) 
B20w group
Fasting plasma glucose 0.987 (0.889-1.096) 0.803
Placental weight 1.010 (1.000-1.020) 0.049
A20w group
Family history of DM 2.537 (1.044-6.163) 0.040
GA 1.860 (1.213-2.853) 0.004
Insulin therapy 2.406 (0.961-6.024) 0.061
B20w group, the subjects diagnosed before 20 weeks of gestation; 
A 20w group, the subjects diagnosed after 20 weeks of gestation; 
DM, diabetes mellitus; GA, glycated albumin.
intolerance in the B20w group (Table 3).
3．Association of postpartum glucose tolerance
status and clinical factors in the A20w group
In the A20w group, postpartum OGTT revealed glu-
cose intolerance in 35 (30%) women (GI subgroup) (IFG,
2; IGT, 31; IFG/IGT, 2) (Table 2).
The GI subgroup had a higher rate of family history of
diabetes than the normal subgroup. GA levels in the GI
subgroup were higher than those in the normal group,
whereas there were no significant differences between
the two subgroups in terms of pre-pregnancy BMI, fast-
ing plasma glucose levels on OGTT, and HbA1c levels.
The GI subgroup had a higher frequency of insulin ther-
apy during pregnancy. Gestational weight gain and gesta-
tional age at delivery were similar between the two sub-
groups.
Multiple logistic regression analysis showed that the
GA level at diagnosis of GDM and family history of dia-
betes were independent predictors for glucose intolerance
in the A20w group (Table 3).
Discussion
This study showed that the 30% women who were diag-
nosed with GDM both before and after 20 weeks of ges-
tation experienced glucose intolerance during the early
postpartum period. Placental weight was an independent
predictor for postpartum glucose intolerance in women
who were diagnosed with GDM before 20 weeks of ges-
tation, and GA levels at diagnosis of GDM and family
history of diabetes were independent predictors in those
who were diagnosed with GDM after 20 weeks of gesta-
tion.
Previous studies from Japan showed that the rate of
abnormal glucose tolerance during the early postpartum
period in patients with GDM diagnosed using the
IADPSG criteria were 17-34%.
１５-１８
The rate of glucose in-
tolerance in our subjects was 30%, which was relatively
high. More than 30% of our subjects were referred from
other hospitals in the locality, hence the severity of glu-
cose intolerance in our subjects may be high.
Identical diagnostic criteria were applied to investigate
hyperglycemic disorders at any period during pregnancy.
Typical GDM occurs due to insufficient insulin produc-
tion against insulin resistance in the second or third tri-
mester of pregnancy. Insulin resistance has not yet en-
hanced in the early half of pregnancy. The pathophysiol-
ogy of GDM diagnosed in early pregnancy is different
from that of the typical GDM diagnosed in late preg-
nancy. In this study, we investigated subjects with GDM
in the early half of pregnancy and late half of pregnancy,
separately. Pre-pregnancy BMI was higher in the B20w
group than in the A20w group. Being overweight or obe-
sity is one of the risk factors for diabetes and GDM.
１９
It is
possible that the patients with obesity or those who were
overweight in the B20w group have had glucose intoler-
ance from pre-pregnancy, however, pre-pregnancy BMI
was not a risk factor for early postpartum glucose intoler-
ance in the B20w group. For women who were over-
weight, obstetricians might have been prompted to assess
glucose tolerance earlier. The B20w group had a higher
fasting plasma glucose levels than the A20w group. It
was reported that fasting plasma glucose level decreased
with increasing gestational age from the 4th week to 24th
week of gestation.
２０
The rate of postpartum glucose intolerance was similar
between the B20w and A20w groups. However, the risk
factors for early postpartum glucose intolerance were pla-
cental weight in the B20w group, and GA levels at diag-
nosis of GDM and family history of diabetes in the
A20w group. These results suggest that predictors for
postpartum glucose intolerance vary depending on the
time of diagnosis of GDM, when using the same diag-
nostic criteria in both early and late pregnancy. Data re-
garding recommended cut-off values of OGTT results to
identify hyperglycemic disorders in early pregnancy are
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still limited. Therefore, further investigations are needed
to define the diagnostic criteria for early GDM.
Women with a history of GDM have an increased risk
of developing type 2 diabetes. High BMI, family history
of diabetes, non-Caucasian ethnicity, advanced maternal
age, early diagnosis of GDM, elevated fasting glucose,
increased HbA1c, use of insulin during pregnancy, multi-
parity, hypertensive disorders in pregnancy, and preterm
labor were associated with a future risk of type 2 diabetes
in a systematic review and meta-analysis.
２１
Moreover,
some women with GDM show glucose intolerance from
the early postpartum period. Recent studies reported that
the risk factors of early postpartum glucose intolerance in
women with GDM were specific ethnicity, HbA1c level
at diagnosis of GDM, glucose levels in OGTT, fasting
plasma glucose, BMI, polycystic ovary syndrome, and
decreased β-cell function.２２-２７ In Japanese women with
GDM, diagnosed using the IADPSG criteria, the 1h- and
2h-glucose levels in diagnostic OGTT, insulinogenic in-
dex, insulin secretion-sensitivity index-2, and insulin
treatment during pregnancy predicted early postpartum
glucose intolerance.
１５-１８
Our study is the first to show that
GA level at the time of GDM diagnosis was a predictor
of early postpartum glucose intolerance. The association
between GA level and postpartum glucose intolerance
was yet to be investigated.
GA is one of the biomarkers used to evaluate glycemic
control. At present, HbA1c is used widely in clinical
practice as a gold standard index of glycemic control.
HbA1c reflects the mean glycemic status over the previ-
ous two months, while GA reflects the mean glycemic
status over the previous three weeks; this difference is as-
sociated with the difference in life spans of erythrocyte
and albumin.
２８
GA provides more rapid and marked indi-
cation of the change in glycemic status than HbA1c. In
addition, it has been known that the HbA1c level in-
creases significantly at the latter stage of pregnancy be-
cause of the increased demand for iron, while GA re-
mains stable throughout pregnancy.
２９，３０
A recent study
showed that the GA level during late pregnancy was sig-
nificantly higher in diabetes mothers whose infants had
neonatal complications.
３１
On the basis of these results, the
Japanese Society of Diabetes and Pregnancy has recom-
mended measurement of GA during pregnancy to prevent
perinatal complications in women with glycemic disor-
ders.
In the B20w group, placental weight was a predictor of
early postpartum glucose intolerance. Increased placental
weight has been reported in pregnant women with
GDM.
３２，３３
Increased placental weight was associated with
maternal insulin resistance
３４
and insulin secretary re-
sponse in early pregnancy.
３５
Furthermore, animal experi-
ments have shown that glucose injections in early preg-
nancy increased placental weight.
３６
These findings sug-
gest that maternal metabolic status in early pregnancy af-
fects placental growth, therefore, women in the B20w
group may have hyperglycemia and hyperinsulinemia
due to insulin resistance from pre-pregnancy or early
pregnancy.
The limitations of this study include the relatively
small sample size and the possibility of selection bias,
because 30% of our subjects were referred from other
hospitals. In addition, it was not verified whether all sub-
jects in the A20w group were free from hyperglycemic
disorder before 20 weeks of gestation. Another limitation
is that breast-feeding, which may affect glucose toler-
ance, was not investigated in this study.
In conclusion, 30% of patients with GDM had glucose
intolerance in the early postpartum period. GA level at
diagnosis of GDM was associated with early postpartum
glucose intolerance among women diagnosed with GDM
after 20 weeks of gestation. GA may be a useful indicator
not only for achievement of metabolic control during
pregnancy but also for predicting postpartum glucose in-
tolerance.
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